New Receptor for Advanced Glycated Endproducts (RAGE) fusion protein and nucleic acids, useful for treating a RAGE-mediated disorder, e.g. amyloidosis, Alzheimer's disease, cancer, kidney failure, or inflammation

摘要

A RAGE fusion protein comprising fully defined 447 or 326 amino acids (SEQ ID NO. 56 or 57), or a sequence at least 90% identical to it, is new. Independent claims are: (1) an isolated DNA molecule that encodes the RAGE fusion protein; (2) an expression vector that encodes the RAGE fusion protein; (3) a cell transfected with the expression vector, so that the cell expresses a RAGE fusion protein comprising SEQ ID NO. 56 or 57, or a sequence at least 90% identical to it; (4) a formulation comprising a lyophilized mixture of a lyoprotectant, a RAGE fusion protein, and a buffer; (5) a reconstituted formulation comprising a lyophylized RAGE fusion protein reconstituted in a diluent, where the RAGE fusion protein concentration in the reconstituted formulation is 1-400 mg/ml; (6) an article of manufacture comprising a container, which holds a lyophylized RAGE fusion protein, and instructions for reconstituting the lyophilized formulation with a diluent; (7) a method for preparing a stable reconstituted formulation of a RAGE fusion protein; and (8) a method of treating a RAGE-mediated disorder in a subject. ACTIVITY : Antidiabetic; Cardiovascular-Gen; Neuroprotective; Nootropic; Cytostatic; Nephrotropic; Antiinflammatory; Gastrointestinal-Gen; Antiulcer; Antirheumatic; Antiarthritic; Antipsoriatic; Vasotropic; Cerebroprotective; Cardiant; Antibacterial; Immunosuppressive; Vulnerary; Osteopathic. The effects of administering TTP-4000 on rejection of syngeneic transplanted islets in diabetic NOD mice were studied. Results showed an increase in the time before detection of graft failure for animals treated with TTP-4000 and TTP-3000 as opposed to animals that are not treated at all. MECHANISM OF ACTION : RAGE-Antagonist.